Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
32.30
+0.22 (0.69%)
Jun 6, 2025, 4:00 PM - Market closed
Cytokinetics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 19.22 | 18.47 | 7.53 | 7.59 | 70.43 | 55.83 | Upgrade
|
| Other Revenue | - | - | - | 87 | - | - | Upgrade
|
| Revenue | 19.22 | 18.47 | 7.53 | 94.59 | 70.43 | 55.83 | Upgrade
|
| Revenue Growth (YoY) | 412.21% | 145.34% | -92.04% | 34.30% | 26.15% | 107.79% | Upgrade
|
| Cost of Revenue | 357.68 | 339.41 | 330.12 | 240.81 | 159.94 | 96.95 | Upgrade
|
| Gross Profit | -338.46 | -320.93 | -322.59 | -146.23 | -89.51 | -41.12 | Upgrade
|
| Selling, General & Admin | 227.18 | 215.31 | 173.61 | 177.98 | 96.8 | 52.82 | Upgrade
|
| Operating Expenses | 227.18 | 215.31 | 173.61 | 177.98 | 96.8 | 52.82 | Upgrade
|
| Operating Income | -565.64 | -536.25 | -496.21 | -324.2 | -186.31 | -93.94 | Upgrade
|
| Interest Expense | -92.14 | -86.51 | -57.67 | -51.16 | -29.33 | -38.68 | Upgrade
|
| Interest & Investment Income | 57.32 | 51.53 | 27.63 | 11.34 | 0.33 | 5.33 | Upgrade
|
| Other Non Operating Income (Expenses) | -14.8 | -18.3 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -615.26 | -589.53 | -526.24 | -364.02 | -215.31 | -127.29 | Upgrade
|
| Other Unusual Items | - | - | - | -24.94 | - | - | Upgrade
|
| Pretax Income | -615.26 | -589.53 | -526.24 | -388.96 | -215.31 | -127.29 | Upgrade
|
| Net Income | -615.26 | -589.53 | -526.24 | -388.96 | -215.31 | -127.29 | Upgrade
|
| Net Income to Common | -615.26 | -589.53 | -526.24 | -388.96 | -215.31 | -127.29 | Upgrade
|
| Shares Outstanding (Basic) | 116 | 112 | 97 | 90 | 77 | 65 | Upgrade
|
| Shares Outstanding (Diluted) | 116 | 112 | 97 | 90 | 77 | 65 | Upgrade
|
| Shares Change (YoY) | 18.23% | 16.01% | 7.46% | 16.83% | 19.16% | 12.07% | Upgrade
|
| EPS (Basic) | -5.30 | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | Upgrade
|
| EPS (Diluted) | -5.30 | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | Upgrade
|
| Free Cash Flow | -407.57 | -399.8 | -415.75 | -310.85 | -191.39 | -2.11 | Upgrade
|
| Free Cash Flow Per Share | -3.51 | -3.57 | -4.31 | -3.46 | -2.49 | -0.03 | Upgrade
|
| Gross Margin | - | - | - | -154.59% | -127.09% | -73.66% | Upgrade
|
| Operating Margin | -2943.30% | -2902.72% | -6589.71% | -342.75% | -264.54% | -168.27% | Upgrade
|
| Profit Margin | -3201.47% | -3191.11% | -6988.63% | -411.21% | -305.72% | -228.00% | Upgrade
|
| Free Cash Flow Margin | -2120.77% | -2164.10% | -5521.23% | -328.64% | -271.76% | -3.78% | Upgrade
|
| EBITDA | -556.14 | -526.72 | -484.31 | -318.39 | -184.04 | -92.11 | Upgrade
|
| EBITDA Margin | - | - | - | - | -261.31% | -164.99% | Upgrade
|
| D&A For EBITDA | 9.5 | 9.53 | 11.89 | 5.81 | 2.28 | 1.83 | Upgrade
|
| EBIT | -565.64 | -536.25 | -496.21 | -324.2 | -186.31 | -93.94 | Upgrade
|
| EBIT Margin | - | - | - | - | -264.54% | -168.27% | Upgrade
|
| Revenue as Reported | 18.47 | 18.47 | 7.53 | 94.59 | 70.43 | 55.83 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.